Catalyst Pharmaceuticals Inc at Citi Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Samantha Semenkow - Citi - Analyst : All right. So as I mentioned, pretty diverse panel here, both the modalities, stage of the company and there's a little bit of overlap on some indications, though, which we'll get into. But maybe we could just kick it off with sharing a little bit about your business model, the types of drugs that you're developing in the neuromuscular space, and what we could look forward to in the future in terms of like some exciting catalysts upcoming? Rich, would you like to start?

Question: Samantha Semenkow - Citi - Analyst : That's great. So thank you for that, and you all mentioned that you have a DMD program. So maybe let's just focus a little bit there. So -- and again, all very different ways of helping to treat these DMD children. So where do each of your drugs fit into the landscape? I mean I think that they can all kind of be used. And is it a age difference? Is it -- we can layer all of these on, depending at the combination sort of therapy? Like I'd love to just hear your thoughts on maybe you guys can have a quick discussion on where each of these fit.

Question: Samantha Semenkow - Citi - Analyst : That's a really good segue then. I mean, can we talk a little bit about the regulatory environment for DMD specifically, but more broadly for just across neuromuscular disorders. What are you seeing? And how do you think about those endpoints where it's maybe a little bit more difficult for some of the populations for those children?

Question: Samantha Semenkow - Citi - Analyst : Paul, I wanted to dive a little bit deeper into the DMD data that you presented earlier this year. One of the things you showed is that you were able to get into the stem cells. Maybe you could just elaborate a little bit about what you've seen and why it's important to be in the stem cells. And what is different about your product that's allowing you to achieve this? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 04, 2024 / 6:00PM, CPRX.OQ - Catalyst Pharmaceuticals Inc at Citi Global Healthcare Conference

Question: Samantha Semenkow - Citi - Analyst : Yes, agreed. Rich, for you. Your AGAMREE launch, it's been about two quarters and change now that we've seen. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. DECEMBER 04, 2024 / 6:00PM, CPRX.OQ - Catalyst Pharmaceuticals Inc at Citi Global Healthcare Conference So I mean, quite strong launch, I guess, can you just talk about -- I talked about a little bit but maybe elaborate on what is the drivers there. What are you seeing in terms of the market dynamics on who is moving to AGAMREE and what can we look forward to as the launch continues?

Question: Samantha Semenkow - Citi - Analyst : Do we know when we'll see the first data from SUMMIT yet?

Question: Samantha Semenkow - Citi - Analyst : Got it. Okay. And then your business model, you are pretty active on the BD front. Can you just maybe just talk about what type of opportunities are most exciting for you and maybe something a flavor of what we could look forward to?

Question: Samantha Semenkow - Citi - Analyst : Exciting. And then, Paul, if I could squeeze one more in for you. We're going to have updated DMD data in the first quarter, and we should hear as you were kind of alluding to a little bit more about your next steps in Huntington's, I think, in the new year as well. Can you just give us a flavor of what we should expect from both of those? And then I'll turn it back to you, call after that.

Question: Samantha Semenkow - Citi - Analyst : Thank you so much. It was a wonderful discussion.